DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials

Grenet, Guillaume; Mekhaldi, Samia; Mainbourg, Sabine; Auffret, Marine; Cornu, Catherine; Cracowski, Jean‐Luc; Gueyffier, François; Lega, Jean‐Christophe; Cucherat, Michel

doi:10.2337/dc20-2018

Cited by 11 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a recent meta-analysis by Yang et al ( 2016 ) illustrated that uses of DPP-4 inhibitors were not related to increased risk of viral infections as compared with placebo. In addition, there is an updated meta-analysis which showed that that using DPP-4 inhibitors was not linked with a higher risk of respiratory viral infections (Grenet et al 2021 ).…”

Section: Dpp-4 Inhibitors and Viral Infectionsmentioning

confidence: 99%

“…The immunological effects of DPP-4 inhibitors are related to the decrease of T cell activity and release of co-stimulatory chemokines and cytokines with upregulation of immunosuppressive cytokines (Yang et al 2016 ; Grenet et al 2021 ). Though these effects were not confirmed in experimental and preclinical studies.…”

Section: Dpp-4 Inhibitors and Viral Infectionsmentioning

confidence: 99%

“…Many recent studies reported that DPP-4 inhibitors are effective in decreasing the severity of SARS-CoV-2 infections (Al-Kuraishy et al 2021e ; Noh et al 2021 ). Of note, DPP-4 receptors are highly expressed in the case of obesity and T2DM (Grenet et al 2021 ). Upregulation of DPP-4 receptors in the respiratory tract in obese and T2DM patients increase the risk for SARS-CoV-2 infection (Noh et al 2021 ).…”

Section: Dpp-4 Inhibitors and Covid-19mentioning

confidence: 99%

See 2 more Smart Citations

Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 (Covid-19) is caused by severe acute respiratory syndrome type 2 (SARS-CoV-2). Covid-19 is characterized by hyperinflammation, oxidative stress, and multi-organ injury (MOI) such as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Covid-19 is mainly presented with respiratory manifestations; however, extra-pulmonary manifestations may also occur. Extra-pulmonary manifestations of Covid-19 are numerous including: neurological, cardiovascular, renal, endocrine, and hematological complications. Notably, a cluster of differentiation 26 (CD26) or dipeptidyl peptidase-4 (DPP-4) emerged as a new receptor for entry of SARS-CoV-2. Therefore, DPP-4 inhibitors like sitagliptin could be effective in treating Covid-19. Hence, we aimed in the present critical review to assess the potential role of sitagliptin in Covid-19. DPP-4 inhibitors are effective against the increased severity of SARS-CoV-2 infections. Moreover, DPP-4 inhibitors inhibit the interaction between DPP-4 and scaffolding proteins which are essential for endosome formation and replication of SARS-CoV-2. Therefore, sitagliptin through attenuation of the inflammatory signaling pathway and augmentation of stromal-derived factor-1 (SDF-1) may decrease the pathogenesis of SARS-CoV-2 infection and could be a possible therapeutic modality in treating Covid-19 patients. In conclusion, the DPP-4 receptor is regarded as a potential receptor for the binding and entry of SARS-CoV-2. Inhibition of these receptors by the DPP-4 inhibitor, sitagliptin, can reduce the pathogenesis of the infection caused by SARS-CoV-2 and their associated activation of the inflammatory signaling pathways.

show abstract

Section: Dpp-4 Inhibitors and Viral Infectionsmentioning

confidence: 99%

Section: Dpp-4 Inhibitors and Viral Infectionsmentioning

confidence: 99%

Section: Dpp-4 Inhibitors and Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Sin embargo, un registro llevado a cabo en Italia exploró la posible asociación entre los iDPP-4 para la diabetes y el riesgo de infección por COVID-19, y se concluyó que los iDPP-4 no parecen tener ningún efecto protector o perjudicial en la incidencia de COVID-19 7 (evidencia 2b) constatando datos recientes sobre su papel neutro en la incidencia de infecciones respiratorias 8 .…”

Section: ¿Los Pacientes En Tratamiento Con Idpp-4 Tienen Mayor O Meno...unclassified

Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19

Carrasco-Sánchez

Carretero-Anibarro²,

Gargallo

et al. 2022

Endocrinología, Diabetes y Nutrición (English ed.)

View full text Add to dashboard Cite

“…Of note, a similar analysis was recently published for dipeptidyl-peptidase-4 inhibitors. 17 Two independent reviewers (DP and AB) extracted the data from the eligible reports using a pilot-tested, data extraction form. We evaluated the following primary outcomes of interest: upper respiratory tract infection, lower respiratory tract infection, viral infection, influenza and ARDS.…”

mentioning

confidence: 99%

Meta‐analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium‐glucose co‐transporter‐2 inhibitors: Implications for the COVID‐19 pandemic

Patoulias

Papadopoulos

Boulmpou

et al. 2021

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

To the Editor:Diabetes represents a pandemic that has been recognized as an independent risk factor for severe infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the context of the coronavirus disease 19 (COVID-19) pandemic, 1 although it may not actually increase the risk for SARS-CoV-2 transmission for patients with diabetes compared with the general population. 2,3 Patients with diabetes feature a twofold increase in the odds for severe SARS-CoV-2 infection and a two-to threefold increase in the odds for death because of disease. 1,4,5 Patients with diabetes experience a significant increase in the risk for in-hospital death because of SARS-CoV-2 infection, as shown in a recent, large nationwide study. 6 Therefore, optimal treatment strategy for these patients becomes a top priority. 7 Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, an antidiabetic drug class with multiple, pleiotropic and beneficial effects, especially in patients with concomitant cardiovascular or renal disease, should be used with caution in the context of infection, because of the increased risk for diabetic ketoacidosis. 8 The anti-inflammatory properties of SGLT-2 inhibitors might be beneficial for infected patients, as they could hypothetically ameliorate the cytokine storm. 9,10 Previous studies have shown the significant reduction in inflammatory markers, such as C-reactive protein, ferritin and interleukin-6, with SGLT-2 inhibitors. 9 In addition, this drug class exerts beneficial effects on endothelial function, a finding that could have potential applicability for the prevention of thrombotic complications among SARS-CoV-2 patients. 11 Recently published observational studies support that SGLT-2 inhibitors are not inferior to incretin-based agents concerning surrogate COVID-19 outcomes, 12 while they might decrease the risk for mechanical ventilation. 13 However, more evidence from clinical practice is required, to identify the impact of antidiabetic drugs administered prior to infection on outcomes of interest among infected patients. 14,15 In addition, the ongoing DARE-19 trial, whose protocol has recently been published in Diabetes, Obesity and Metabolism, will provide answers on whether dapagliflozin could prevent COVID-19-related complications and all-cause mortality in patients admitted with SARS-CoV-2 infection. 16 We sought to determine whether SGLT-2 inhibitors influence the risk for respiratory tract infections and acute respiratory distress syndrome (ARDS), pooling data from the published cardiovascular and renal outcome, placebo-controlled trials until November 2020.

show abstract

DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials

Cited by 11 publications

References 5 publications

Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?

Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?

Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19

Meta‐analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium‐glucose co‐transporter‐2 inhibitors: Implications for the COVID‐19 pandemic

Contact Info

Product

Resources

About